Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
pharmafile | September 11, 2019 | News story | Research and Development | Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period in the treatment of relapsing multiple sclerosis (MS).
Focusing on new data from an ongoing Phase 3 extension study examining patients with at least 10 years of follow up, it was found that 51% of Tecfidera patients remained relapse free for the duration of the study. Additionally, 64% saw no confirmed disability progression, while 79% maintained the ability to walk with no significant disability
Biogen also released details from a meta-analysis compiling data from 18 databases of real-world studies, confirming that Tecfidera outclassed other diease-modifying therapies for relapsing MS including interferon beta, glatiramer acetate and teriflunomide in reducing annualised relapse rate, as well as in delaying time until first relapse.
Updated interim data for diroximel fumarate, an experimental treatment developed by Biogen and Alkermes, was also revealed, demonstrating, in 888 patients treated for a median of 18 months, that the therapy was generally well-tolerated, in line with previous data.
“Biogen’s new data underscore Tecfidera’s role as a meaningful long-term therapy option for relapsing MS, with many patients in the study experiencing no relapses or progression in their disability over a 10-year period,” said Dr Alfred Sandrock Jr, Executive Vice President and Chief Medical Officer at Biogen. “We are proud of the strong legacy Tecfidera has achieved over the years and are excited to continue building our franchise of fumarate products with the potential addition of diroximel fumarate. As a next-generation fumarate, diroximel fumarate offers a differentiated gastrointestinal tolerability profile and, if approved, will be a strong choice for physicians and patients with relapsing MS to consider.”
Matt Fellows
Related Content
Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
Biogen’s biosimilar Tofidence approved by FDA
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
